4
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T8825 |
Capmatinib 2HCl.H2O
INCB28060 2HCl.H2O,INC-280 2HCl.H2O,NVP-INC280 2HCl.H2O |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) 是一种具有潜在抗肿瘤活性的原癌基因 c-Met (HGFR) 的口服生物可利用抑制剂。 | |||
T1963 |
Capmatinib
NVP-INC280,INC-280,卡马替尼,INCB28060 |
Apoptosis; c-Met/HGFR | Apoptosis; Tyrosine Kinase/Adaptors |
Capmatinib (INCB28060) 是一种具有口服活性的,选择性的,ATP 竞争性的c-Met 激酶抑制剂,IC50值为0.13 nM。它有效抑制 c-Met 依赖性肿瘤细胞的增殖和迁移,可诱导细胞凋亡,有抗肿瘤活性。 | |||
T8416 |
Capmatinib xHCl
INCB28060,Capmatinib hydrochloride(free base),INC280 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Capmatinib xHCl (INCB28060) 是一种有效的、口服活性的、选择性的和 ATP 竞争性 c-Met 激酶抑制剂,有效地阻断体外激酶活性 (IC50 = 0.13 nM) 以及在细胞中的组成型或 HGF 刺激活性(IC50 值范围从 0.3 到1.1纳米)。 | |||
T4260 |
Capmatinib 2HCl
INC-280 2HCl,INCB28060盐酸盐,INCB28060 2HCl |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Capmatinib 2HCl (INC-280 2HCl) 是一种新型的 ATP 竞争性 c-MET 激酶抑制剂,IC50 为 0.13 nM。它具有皮摩尔酶效,对 c-MET 具有高度特异性,选择性超过 10, 000 倍一大组人类激酶。该抑制剂在 c-MET 依赖性肿瘤细胞系中有效阻断 c-MET 磷酸化和其关键下游效应子的激活。因此,它在体外有效抑制 c-MET 依赖性肿瘤细胞增殖和迁移,并有效诱导细胞凋亡。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-01879 |
S100A14 Protein, Human, Recombinant (His)
S100 calcium binding protein A14,BCMP84,S100A15 |
Human | E. coli |
S100 protein is a family of low molecular weight protein found in vertebrates characterized by two EF-hand calcium-binding motifs. There are at least 21 different S100 proteins, and the name is derived from the fact that the protein is 100% soluble in ammonium sulfate at neutral pH. Most S100 proteins are disulfide-linked homodimer, and is normally present in cells derived from theneural crest, chondrocytes, macrophages, dendritic cells, etc. S100 proteins have been implicated in a variety of in... |